Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Prion diseases are transmissible neurodegenerative conditions characterized by the accumulation of protease-resistant forms of the prion protein (PrP), termed PrPres, in the brain. Insoluble PrPres tends to aggregate into amyloid fibrils. The anthracycline 4′-iodo-4′-deoxy-doxorubicin (IDX) binds to amyloid fibrils and induces amyloid resorption in patients with systemic amyloidosis. To test IDX in an experimental model of prion disease, Syrian hamsters were inoculated intracerebrally either with scrapie-infected brain homogenate or with infected homogenate coincubated with IDX. In IDX-treated hamsters, clinical signs of disease were delayed and survival time was prolonged. Neuropathological examination showed a parallel delay in the appearance of brain changes and in the accumulation of PrPres and PrP amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pan, K. M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R. J., & Cohen, F. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10962 · Cited by 2,277
Molecular Biology of Prion Diseases
Prusiner, S. B. (1991) · Science · doi:10.1126/science.1675487 · Cited by 1,988
Scrapie prions aggregate to form amyloid-like birefringent rods
Prusiner, S. B., McKinley, M. P., Bowman, K. A., Bolton, D. C., Bendheim, P. E., Groth, D. F., & Glenner, G. G. (1983) · Cell · doi:10.1016/0092-8674(83)90168-x · Cited by 1,043
Neurotoxicity of a prion protein fragment
Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., & Tagliavini, F. (1993) · Nature · doi:10.1038/362543a0 · Cited by 943
Self-citationCaughey, B. W., Dong, A., Bhat, K. S., Ernst, D., Hayes, S. F., & Caughey, W. S. (1991) · Biochemistry · doi:10.1021/bi00245a003 · Cited by 822
Role of microglia and host prion protein in neurotoxicity of a prion protein fragment
Brown, D. R., Schmidt, B., & Kretzschmar, H. A. (1996) · Nature · doi:10.1038/380345a0 · Cited by 502
Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein.
Safar, J., Roller, P. P., Gajdusek, D. C., & Gibbs, C. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80725-x · Cited by 378
Bruce, M. E., McBride, P. A., & Farquhar, C. F. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90298-x · Cited by 277
Prion diseases of humans and animals
Prusiner, S. B., Telling, G., Cohen, F. E., & DeArmond, S. J. (1996) · Seminars in Virology · doi:10.1006/smvy.1996.0021 · Cited by 234
Potent Inhibition of Scrapie‐Associated PrP Accumulation by Congo Red
Caughey, B., & Race, R. E. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09437.x · Cited by 233
Cited by
Prion Diseases of Humans and Animals: Their Causes and Molecular Basis
Collinge, J. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.519 · Cited by 1,344
Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis
Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P.-C., Brandner, S., & Collinge, J. (2003) · Science · doi:10.1126/science.1090187 · Cited by 770
Aguzzi, A., & Polymenidou, M. (2004) · Cell · doi:10.1016/s0092-8674(03)01031-6 · Cited by 544
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
Doh-ura, K., Iwaki, T., & Caughey, B. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4894-4897.2000 · Cited by 324
Porphyrin and Phthalocyanine Antiscrapie Compounds
Priola, S. A., Raines, A., & Caughey, W. S. (2000) · Science · doi:10.1126/science.287.5457.1503 · Cited by 302
A systematic review of prion therapeutics in experimental models
Trevitt, C. R. (2006) · Brain · doi:10.1093/brain/awl150 · Cited by 263
Elimination of prions by branched polyamines and implications for therapeutics
Supattapone, S., Nguyen, H.-O. B., Cohen, F. E., Prusiner, S. B., & Scott, M. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14529 · Cited by 259
Anti‐amyloidogenic activity of tetracyclines: studies in vitro
Forloni, G., Colombo, L., Girola, L., Tagliavini, F., & Salmona, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02380-2 · Cited by 242
Self-citationGames Played by Rogue Proteins in Prion Disorders and Alzheimer's Disease
Aguzzi, A., & Haass, C. (2003) · Science · doi:10.1126/science.1087348 · Cited by 225
Branched Polyamines Cure Prion-Infected Neuroblastoma Cells
Supattapone, S., Wille, H., Uyechi, L., Safar, J., Tremblay, P., Szoka, F. C., Cohen, F. E., Prusiner, S. B., & Scott, M. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.7.3453-3461.2001 · Cited by 221
Tagliavini, F., Forloni, G., Colombo, L., Rossi, G., Girola, L., Canciani, B., Angeretti, N., Giampaolo, L., Peressini, E., Awan, T., et al. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3840 · Cited by 173
Self-citationChallenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
“1 3 have been chosen particularly due to the structural analogies of tetracycline with Congo red (an azo dye used for specific detection of pathological Aβ aggregation seen as apple-green birefringence under polarized light) (Ladewig 1945), and iododoxorubicin (an anthracycline anti-cancer drug which inhibits the form…”
Background
Metadata
- Authors
- Tagliavini, F., McArthur, R. A., Canciani, B., Giaccone, G., Porro, M., Bugiani, M., Lievens, P. M.-J., Bugiani, O., Peri, E., Dall’Ara, P., Rocchi, M., Poli, G., Forloni, G., Bandiera, T., Varasi, M., Suarato, A., Cassutti, P., Cervini, M. A., Lansen, J., Salmona, M., & Post, C.
- Venue
- Science
- Published
- 1997-05-16
- Volume
- 276
- Issue
- 5315
- Pages
- 1119-1121
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2148417883
- Cited by
- 176
- References
- 23
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.